155 related articles for article (PubMed ID: 31540689)
21. P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro.
Kim WY; Benet LZ
Pharm Res; 2004 Jul; 21(7):1284-93. PubMed ID: 15290871
[TBL] [Abstract][Full Text] [Related]
22. Drug Elimination Alteration in Acute Lymphoblastic Leukemia Mediated by Renal Transporters and Glomerular Filtration.
Zhou Y; Du B; Kan M; Chen S; Tang BH; Nie AQ; Ye PP; Shi HY; Hao GX; Guo XL; Han QJ; Zheng Y; Zhao W
Pharm Res; 2020 Aug; 37(8):158. PubMed ID: 32743772
[TBL] [Abstract][Full Text] [Related]
23. Ex vivo and in vivo investigations of the effects of extracts of Vernonia amygdalina, Carica papaya and Tapinanthus sessilifolius on digoxin transport and pharmacokinetics: assessing the significance on rat intestinal P-glycoprotein efflux.
Oga EF; Sekine S; Horie T
Drug Metab Pharmacokinet; 2013; 28(4):314-20. PubMed ID: 23291634
[TBL] [Abstract][Full Text] [Related]
24. Developmental expression of multidrug resistance phosphoglycoprotein (P-gp) in the mouse fetal brain and glucocorticoid regulation.
Petropoulos S; Gibb W; Matthews SG
Brain Res; 2010 Oct; 1357():9-18. PubMed ID: 20709040
[TBL] [Abstract][Full Text] [Related]
25. Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations.
Scotcher D; Jones CR; Galetin A; Rostami-Hodjegan A
J Pharmacol Exp Ther; 2017 Mar; 360(3):484-495. PubMed ID: 28057840
[TBL] [Abstract][Full Text] [Related]
26. Nephrotoxicity and Kidney Transport Assessment on 3D Perfused Proximal Tubules.
Vormann MK; Gijzen L; Hutter S; Boot L; Nicolas A; van den Heuvel A; Vriend J; Ng CP; Nieskens TTG; van Duinen V; de Wagenaar B; Masereeuw R; Suter-Dick L; Trietsch SJ; Wilmer M; Joore J; Vulto P; Lanz HL
AAPS J; 2018 Aug; 20(5):90. PubMed ID: 30109442
[TBL] [Abstract][Full Text] [Related]
27. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein.
Mayer U; Wagenaar E; Beijnen JH; Smit JW; Meijer DK; van Asperen J; Borst P; Schinkel AH
Br J Pharmacol; 1996 Nov; 119(5):1038-44. PubMed ID: 8922756
[TBL] [Abstract][Full Text] [Related]
28. Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin.
Hsin CH; Stoffel MS; Gazzaz M; Schaeffeler E; Schwab M; Fuhr U; Taubert M
Sci Rep; 2020 Jul; 10(1):12457. PubMed ID: 32719417
[TBL] [Abstract][Full Text] [Related]
29. Loxapine P-glycoprotein interactions in vitro.
Reed A; Huie K; Perloff ES; Cassella JV; Takahashi LH
Drug Metab Lett; 2012 Mar; 6(1):26-32. PubMed ID: 22300294
[TBL] [Abstract][Full Text] [Related]
30. Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism.
Akamine Y; Yasui-Furukori N; Uno T
Curr Drug Metab; 2019; 20(2):124-129. PubMed ID: 30280663
[TBL] [Abstract][Full Text] [Related]
31. Regulation of P-glycoprotein in renal proximal tubule epithelial cells by LPS and TNF-alpha.
Heemskerk S; Peters JG; Louisse J; Sagar S; Russel FG; Masereeuw R
J Biomed Biotechnol; 2010; 2010():525180. PubMed ID: 20300455
[TBL] [Abstract][Full Text] [Related]
32. Characterization of P-Glycoprotein Humanized Mice Generated by Chromosome Engineering Technology: Its Utility for Prediction of Drug Distribution to the Brain in Humans.
Yamasaki Y; Kobayashi K; Okuya F; Kajitani N; Kazuki K; Abe S; Takehara S; Ito S; Ogata S; Uemura T; Ohtsuki S; Minegishi G; Akita H; Chiba K; Oshimura M; Kazuki Y
Drug Metab Dispos; 2018 Nov; 46(11):1756-1766. PubMed ID: 29777024
[TBL] [Abstract][Full Text] [Related]
33. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.
Dirson G; Fernandez C; Hindlet P; Roux F; German-Fattal M; Gimenez F; Farinotti R
Pharm Res; 2006 Jul; 23(7):1525-32. PubMed ID: 16779703
[TBL] [Abstract][Full Text] [Related]
34. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.
Zhou SF
Xenobiotica; 2008 Jul; 38(7-8):802-32. PubMed ID: 18668431
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin.
Goralski KB; Hartmann G; Piquette-Miller M; Renton KW
Br J Pharmacol; 2003 May; 139(1):35-48. PubMed ID: 12746221
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics.
Hughes J; Crowe A
J Pharmacol Sci; 2010; 113(4):315-24. PubMed ID: 20724802
[TBL] [Abstract][Full Text] [Related]
37. The effect of 17α-ethynylestradiol induced intrahepatic cholestasis of pregnancy on placental P-glycoprotein in mice: Implications in the individualized transplacental digoxin treatment for fetal heart failure.
Wang C; Zhang Y; Zhan Y; Luo C; Li Y; Qiu D; Mu D; Duan H; Zhou K; Hua Y
Placenta; 2016 Aug; 44():91-7. PubMed ID: 27452443
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities.
Kirby B; Kharasch ED; Thummel KT; Narang VS; Hoffer CJ; Unadkat JD
J Clin Pharmacol; 2006 Nov; 46(11):1313-9. PubMed ID: 17050796
[TBL] [Abstract][Full Text] [Related]
39. Impact of reduced P-glycoprotein function on digoxin concentrations in patients with dementia.
Ali I; Guidone D; Nicolazzo JA; Brouwer KLR
Br J Clin Pharmacol; 2019 Oct; 85(10):2351-2359. PubMed ID: 31269278
[TBL] [Abstract][Full Text] [Related]
40. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.
Becquemont L; Glaeser H; Drescher S; Hitzl M; Simon N; Murdter TE; Heinkele G; Hofmann U; Schaefer C; Burk O; Verstuyft C; Eichelbaum M; Fromm MF
Clin Pharmacol Ther; 2006 May; 79(5):449-60. PubMed ID: 16678547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
